Interactions between posaconazole and Alfuzosin extended release (alfuzosin)
alfuzosin and posaconazole (Major Drug-Drug)
CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and pharmacologic effects of alfuzosin, which is primarily metabolized by the isoenzyme. Severe hypotension could result. Repeated administration of 400 mg of ketoconazole, a potent CYP450 3A4 inhibitor, increased alfuzosin peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 2.3- and 3.2-fold, respectively, following a single 10 mg dose of alfuzosin.
MANAGEMENT: Concomitant use of alfuzosin with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated.
